-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Monte Rosa Therapeutics, Lowers Price Target to $27

Benzinga·08/03/2026 13:18:36
Listen to the news
Wedbush analyst Robert Driscoll maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform and lowers the price target from $37 to $27.